ATE372117T1 - Verwendung von 1,3-diazadibenzo(e,h) azulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems - Google Patents

Verwendung von 1,3-diazadibenzo(e,h) azulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems

Info

Publication number: ATE372117T1
Authority: AT; Austria
Prior art keywords: disorders; azulenes; diseases; prevention; treatment
Prior art date: 2003-11-21

Application number

AT04798735T

Other languages

English (en)

Inventor

Mladen Mercep

Milan Mesic

Renata Rupcic

Dijana Pesic

Original Assignee

Glaxosmithkline Zagreb

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-21

Filing date

2004-11-19

Publication date

2007-09-15

2004-11-19 Application filed by Glaxosmithkline Zagreb filed Critical Glaxosmithkline Zagreb

2007-09-15 Application granted granted Critical

2007-09-15 Publication of ATE372117T1 publication Critical patent/ATE372117T1/de

Links

210000003169 central nervous system Anatomy 0.000 title abstract 3
150000001545 azulenes Chemical class 0.000 title 1
208000037765 diseases and disorders Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
230000002265 prevention Effects 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
SLMBFUGNHXWDID-UHFFFAOYSA-N 3,5-diazatetracyclo[12.4.0.02,6.07,12]octadeca-1,3,5,7,9,11,13,15,17-nonaene Chemical class C1=C2C=CC=CC2=C2N=CN=C2C2=CC=CC=C21 SLMBFUGNHXWDID-UHFFFAOYSA-N 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
230000000035 biogenic effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000006806 disease prevention Effects 0.000 abstract 1
230000001722 neurochemical effect Effects 0.000 abstract 1
239000002858 neurotransmitter agent Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Anesthesiology (AREA)
Pulmonology (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT04798735T 2003-11-21 2004-11-19 Verwendung von 1,3-diazadibenzo(e,h) azulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems ATE372117T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HR20030958A HRP20030958A2 (en)	2003-11-21	2003-11-21	USE OF 1,3-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS

Publications (1)

Publication Number	Publication Date
ATE372117T1 true ATE372117T1 (de)	2007-09-15

Family

ID=34611162

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04798735T ATE372117T1 (de)	2003-11-21	2004-11-19	Verwendung von 1,3-diazadibenzo(e,h) azulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems

Country Status (10)

Country	Link
US (1)	US20070129330A1 (de)
EP (1)	EP1684749B1 (de)
JP (1)	JP2007512310A (de)
CN (1)	CN1897938A (de)
AT (1)	ATE372117T1 (de)
CA (1)	CA2547842A1 (de)
DE (1)	DE602004008796T2 (de)
ES (1)	ES2290774T3 (de)
HR (1)	HRP20030958A2 (de)
WO (1)	WO2005049016A1 (de)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3711489A (en) *	1971-03-31	1973-01-16	Pfizer	Certain 8,9-dihydro(3,4,7,8)cycloocta(1,2-d)imidazoles
NL7605526A (nl) *	1976-05-24	1977-11-28	Akzo Nv	Nieuwe tetracyclische derivaten.
US4198421A (en) *	1978-11-30	1980-04-15	E. I. Du Pont De Nemours And Company	Antiinflammatory 2-substituted-dibenzo[2,3:6,7]oxepino[4,5-d]imidazoles
FR2504140A1 (fr) *	1981-04-16	1982-10-22	Centre Nat Rech Scient	Nouveaux derives tetracycliques de la dibenzazepine, leur procede de preparation et les compositions pharmaceutiques en renfermant
AU639301B2 (en) *	1990-01-11	1993-07-22	Pharmacia & Upjohn Company	New centrally acting 6,7,8,9-tetrahydro-3h-benz(e)indole heterocyclics
EE03612B1 (et) *	1996-04-12	2002-02-15	Janssen Pharmaceutica N.V.	Asendatud tetratsüklilised tetrahüdrofuraanderivaadid
UA52778C2 (uk) *	1997-10-10	2003-01-15	Янссен Фармацевтика Н.В.	Галогенозаміщені тетрациклічні похідні тетрагідрофурану, спосіб їх отримання та композиція на їх основі
HRP20020453A2 (en) *	2002-05-23	2003-12-31	Pliva D D	1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof

2003
- 2003-11-21 HR HR20030958A patent/HRP20030958A2/hr not_active Application Discontinuation
2004
- 2004-11-19 WO PCT/HR2004/000056 patent/WO2005049016A1/en not_active Ceased
- 2004-11-19 CN CNA2004800383817A patent/CN1897938A/zh active Pending
- 2004-11-19 AT AT04798735T patent/ATE372117T1/de not_active IP Right Cessation
- 2004-11-19 US US10/595,936 patent/US20070129330A1/en not_active Abandoned
- 2004-11-19 DE DE602004008796T patent/DE602004008796T2/de not_active Expired - Lifetime
- 2004-11-19 ES ES04798735T patent/ES2290774T3/es not_active Expired - Lifetime
- 2004-11-19 CA CA002547842A patent/CA2547842A1/en not_active Abandoned
- 2004-11-19 EP EP04798735A patent/EP1684749B1/de not_active Expired - Lifetime
- 2004-11-19 JP JP2006540633A patent/JP2007512310A/ja active Pending

Also Published As

Publication number	Publication date
HRP20030958A2 (en)	2005-08-31
WO2005049016A1 (en)	2005-06-02
DE602004008796D1 (de)	2007-10-18
HK1098668A1 (en)	2007-07-27
DE602004008796T2 (de)	2008-06-12
EP1684749B1 (de)	2007-09-05
JP2007512310A (ja)	2007-05-17
US20070129330A1 (en)	2007-06-07
CN1897938A (zh)	2007-01-17
CA2547842A1 (en)	2005-06-02
ES2290774T3 (es)	2008-02-16
EP1684749A1 (de)	2006-08-02

Similar Documents

Publication	Publication Date	Title
MY144483A (en)	2011-09-30	1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
DE60126980D1 (de)	2007-04-12	Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
CY1111070T1 (el)	2015-06-11	Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
TW200420550A (en)	2004-10-16	Thiazole compounds for the treatment of neurodegenerative disorders
DE60229530D1 (de)	2008-12-04	Substituierte piperazine als modulatoren des melanocortinrezeptors
IL146403A0 (en)	2002-07-25	Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
UA83899C2 (uk)	2008-08-26	Сполуки імідазолу для лікування нейродегенеративних розладів
ATE478669T1 (de)	2010-09-15	Zusammenstellungen und methoden zur behandlung der alzheimerschen krankheit, schäden des zentralnervensystems und entzündlichen erkrankungen
TW200502221A (en)	2005-01-16	Novel lactams and uses thereof
NO20050851L (no)	2005-03-29	Kaspase-inhibitorer og anvendelser derav
ATE409176T1 (de)	2008-10-15	1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
TW200635903A (en)	2006-10-16	Therapeutic agents
ATE357438T1 (de)	2007-04-15	1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE367387T1 (de)	2007-08-15	Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
TW200633986A (en)	2006-10-01	Therapeutic agents
TW200509933A (en)	2005-03-16	Therapeutic agents
NO20071466L (no)	2007-04-19	3-substituerte-5- og 6-aminoalkyl indol-2-karboksylsyreamider og relaterte analoger som inhibitorer av kaseinkinase IE
TW200602297A (en)	2006-01-16	Sulfonamide compounds for the treatment of neurodegenerative disorders
ATE373476T1 (de)	2007-10-15	Verwendung von 2-thia-dibenzo(e,h)azulenen zur behandlung und prävention von erkrankungen und störungen des zentralen nervensystems
TW200504036A (en)	2005-02-01	Novel lactams and uses thereof
DE602004008960D1 (de)	2007-10-25	Verwendung von 1-thiadibenzo e,h azulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems
ATE420637T1 (de)	2009-01-15	Verwendung von 1,2-diazadibenzoäe,hüazulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems
ATE420635T1 (de)	2009-01-15	Verwendung von 1-oxadibenzo äe,hü azulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems
ATE372117T1 (de)	2007-09-15	Verwendung von 1,3-diazadibenzo(e,h) azulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems
ATE365556T1 (de)	2007-07-15	Verwendung von 3-aza-aoxa-dibenzo(e,h)azulenen zur herstellung von pharmazeutischen formulierung für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems

Legal Events

Date	Code	Title	Description
2008-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties